Osteoprotegerin and the Pancreatic Beta Cell
骨保护素和胰腺β细胞
基本信息
- 批准号:8886641
- 负责人:
- 金额:$ 40.87万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-04-01 至 2019-01-31
- 项目状态:已结题
- 来源:
- 关键词:AminesBeta CellBindingBiologyCationsCell DeathCell ProliferationCell SurvivalCellsCellular StressCessation of lifeClinicalDataDevelopmentDiabetes MellitusDiabetic mouseFDA approvedFigs - dietaryFutureGoalsGrowthHumanImmuneIn VitroInsulin-Dependent Diabetes MellitusKnowledgeLeadLigandsMediatingMetabolicModelingMonoclonal AntibodiesMusNF-kappa BNatural regenerationNecrosisNon-Insulin-Dependent Diabetes MellitusNuclearOsteoporosisOutcomeOutcome StudyPancreasPancreatectomyPathway interactionsPharmaceutical PreparationsPhysiologicalRegulationReticulumRodentRoleSignal PathwayStimulusStressStructure of beta Cell of isletTNF geneTNFSF10 geneTRANCE proteinTestingTherapeuticTumor Necrosis Factor-alphaTumor necrosis factor receptor 11bbasebonecell growthcytokinedrug developmentendoplasmimprovedin vivoinsulin dependent diabetes mellitus onsetisletmannovelprolylvalinepublic health relevancereceptorsuccess
项目摘要
DESCRIPTION (provided by applicant): Diabetes results from a reduction in endogenous functional pancreatic βcell mass. Therefore, a priority in the field is to identify agents that enhance functional βcell growth, regeneration, and survival, under conditions of increased βcell stress and demand in vivo. We have recently discovered osteoprotegerin (OPG) to be a novel downstream target of lactogens in the βcell. Preliminary studies indicate that OPG can induce endogenous rodent βcell replication in vivo, human βcell proliferation in vitro, delay onset of Type 1 diabetes in mice, and improve human βcell survival against glucolipotoxicityand cytokineinduced cell death. OPG is a soluble decoy receptor. It acts by binding to its endogenous targets receptor activator of nuclear factor kappaB (RANK) ligand (RANKL) or tumor necrosis factor related apoptosisinducing ligand (TRAIL), and inhibiting their interaction with the respective receptors, RANK and death receptor. In βcells, we found OPG induces human βcell proliferation through inhibition of the RANKL/RANK interaction. We further confirmed the importance of this pathway using Denosumab, an FDAapproved drug for osteoporosis, and a monoclonal antibody that specifically inhibits only the RANKL/RANK pathway. Denosumab also enhances human βcell proliferation and survival. Based on the cumulative evidence we hypothesize that OPG and Denosumab through inhibition of the RANKL/RANK pathway will have a significant therapeutic, physiologic, and mechanistic impact on the βcell, under conditions of increased stress/demand. We will test our hypothesis through the following Specific Aims: SA 1: To assess the in vivotherapeutic potential of OPG on rodent and human βcells under pathophysiologic conditions of increased stress and demand. SA 2: To establish the physiologic role of the RANKL/RANK pathwayin βcells. SA 3: To understand the regulation and the intracellular mechanism of action of OPG and its partners in rodent and human βcells. The clinical impact of the findings come from testing the effects of this pathway in
vivo, in models of increased metabolic demand on rodent and human βcells, identifying downstream targets for future drug development, and the potential for repurposing an osteoporosis drug, Denosumab, for the treatment of diabetes. The studies proposed in this application are novel, timely, and promising, with a high potential for success, based on the persuasive preliminary data. Thus, positive outcomes from these studies could have significant translationalpotential.
描述(由申请方提供):糖尿病由内源性功能性胰腺β细胞质量减少引起。因此,本领域的优先事项是鉴定在体内β细胞应激和需求增加的条件下增强功能性β细胞生长、再生和存活的试剂。我们最近发现骨保护素(OPG)是β细胞中催乳素的一个新的下游靶点。初步研究表明,OPG在体内可诱导内源性啮齿类动物β细胞复制,在体外可诱导人β细胞增殖,可延缓小鼠1型糖尿病的发病,并可提高人β细胞抵抗糖脂毒性和甜菜碱诱导的细胞死亡的存活率。OPG是一种可溶性诱饵受体。其通过与其内源性靶点核因子κ B受体激活因子(RANK)配体(RANKL)或肿瘤坏死因子相关凋亡诱导配体(TRAIL)结合,并抑制其与相应受体RANK和死亡受体的相互作用而发挥作用。在β细胞中,我们发现OPG通过抑制RANKL/RANK相互作用诱导人β细胞增殖。我们使用FDA批准的治疗骨质疏松症的药物狄诺塞单抗和一种仅特异性抑制RANKL/RANK通路的单克隆抗体进一步证实了该通路的重要性。Denosumab还可增强人β细胞增殖和存活。基于累积证据,我们假设OPG和Denosumab通过抑制RANKL/RANK通路,在应激/需求增加的条件下对β细胞产生显著的治疗、生理和机制影响。我们将通过以下特定目的检验我们的假设:SA 1:评估在应激和需求增加的病理生理条件下OPG对啮齿动物和人β细胞的体内治疗潜力。SA 2:研究RANKL/RANK通路在β细胞中的生理作用。SA 3:了解OPG及其伴侣在啮齿动物和人β细胞中的调节和细胞内作用机制。这些发现的临床影响来自于测试这一途径在
在啮齿动物和人类β细胞代谢需求增加的模型中,确定未来药物开发的下游靶点,以及将骨质疏松症药物Denosumab重新用于治疗糖尿病的潜力。基于有说服力的初步数据,本申请中提出的研究是新颖的,及时的,有前途的,具有很高的成功潜力。因此,这些研究的积极结果可能具有显著的预防潜力。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Rupangi C Vasavada其他文献
Rupangi C Vasavada的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Rupangi C Vasavada', 18)}}的其他基金
Parathyroid Hormone-related Protein and the Pancreatic Beta Cell
甲状旁腺激素相关蛋白和胰腺β细胞
- 批准号:
8577579 - 财政年份:2012
- 资助金额:
$ 40.87万 - 项目类别:
Parathyroid Hormone-Related Protein and the Pancreatic Beta Cell
甲状旁腺激素相关蛋白和胰腺β细胞
- 批准号:
8008634 - 财政年份:2009
- 资助金额:
$ 40.87万 - 项目类别:
Parathyroid Hormone-Related Protein and the Pancreatic Beta Cell
甲状旁腺激素相关蛋白和胰腺β细胞
- 批准号:
7662453 - 财政年份:2008
- 资助金额:
$ 40.87万 - 项目类别:
Parathyroid Hormone-Related Protein and the Pancreatic Beta Cell
甲状旁腺激素相关蛋白和胰腺β细胞
- 批准号:
8089556 - 财政年份:2008
- 资助金额:
$ 40.87万 - 项目类别:
相似海外基金
Deep Learning prediction of pancreatic Beta cell transcription factor binding site using Cap analysis gene expression sequencing data
使用 Cap 分析基因表达测序数据深度学习预测胰腺 Beta 细胞转录因子结合位点
- 批准号:
558422-2020 - 财政年份:2020
- 资助金额:
$ 40.87万 - 项目类别:
Canadian Graduate Scholarships Foreign Study Supplements
Analysis of the Role of Post-Transcriptional Regulation by the Poly(C) Binding Proteins in Pancreatic Beta Cell Homeostasis
聚 (C) 结合蛋白转录后调节在胰腺 β 细胞稳态中的作用分析
- 批准号:
10213016 - 财政年份:2019
- 资助金额:
$ 40.87万 - 项目类别:
Analysis of the Role of Post-Transcriptional Regulation by the Poly(C) Binding Proteins in Pancreatic Beta Cell Homeostasis
聚 (C) 结合蛋白转录后调节在胰腺 β 细胞稳态中的作用分析
- 批准号:
10020171 - 财政年份:2019
- 资助金额:
$ 40.87万 - 项目类别:
The role of PDZ binding kinase in beta cell proliferation during pregnancy
PDZ结合激酶在妊娠期β细胞增殖中的作用
- 批准号:
17K09846 - 财政年份:2017
- 资助金额:
$ 40.87万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Investigating the Role of PHIP (Pleckstrin Homology Domain Binding Interacting Protein)in Beta-cell Function
研究 PHIP(Pleckstrin 同源结构域结合相互作用蛋白)在 β 细胞功能中的作用
- 批准号:
225398 - 财政年份:2011
- 资助金额:
$ 40.87万 - 项目类别:
Studentship Programs
IGF binding protein-3 in beta cell apoptosis
IGF 结合蛋白 3 在 β 细胞凋亡中的作用
- 批准号:
6605903 - 财政年份:2001
- 资助金额:
$ 40.87万 - 项目类别:
IGF binding protein-3 in beta cell apoptosis
IGF 结合蛋白 3 在 β 细胞凋亡中的作用
- 批准号:
6773831 - 财政年份:2001
- 资助金额:
$ 40.87万 - 项目类别:
IGF binding protein-3 in beta cell apoptosis
IGF 结合蛋白 3 在 β 细胞凋亡中的作用
- 批准号:
6891873 - 财政年份:2001
- 资助金额:
$ 40.87万 - 项目类别: